Definium Therapeutics, Inc. (DFTX) has 23 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 5 sales totalling $2.6M. Most recent filing: Sept. 18, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 18, 2026 | Krebs Andreas Director | $57,862 | 3,258 | — | No | |
|
|
||||||
| Sept. 18, 2026 | Vallone Carol A Director | $38,575 | 2,172 | — | No | |
|
|
||||||
| Sept. 14, 2026 | Barrow Robert Chief Executive Officer | $0 | 750,000 | +50% | No | |
|
|
||||||
| Sept. 14, 2026 | Wiley Matthew T. Chief Commercial Officer | $0 | 125,000 | +53% | No | |
|
|
||||||
| Sept. 14, 2026 | Karlin Daniel Chief Medical Officer | $0 | 200,000 | +33% | No | |
|
|
||||||
Showing the 5 most recent of 23 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free